#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2274	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2017	211.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1670	1670	T	250	T	155	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2274	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2017	211.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1404	1404	C	287	C	182	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4298	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3443	234.2	0	.	n	.	0	A9G	SNP	9	9	A	262	262	G	240	G	165	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4298	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3443	234.2	0	.	n	.	0	T695C	SNP	695	695	T	948	948	C	309	C,G	191,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4298	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3443	234.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2224	2224	C	229	C	147	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4298	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3443	234.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2850	2850	T	241	T	155	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4298	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3443	234.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2298	2298	A	220	A	141	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	140	folP	855	855	99.77	folP.l15.c4.ctg.1	1648	16.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1079	1081	AGC	29;29;28	A;G;C	19;19;17	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3332	22.6	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1029	1031	ATA	31;28;24	A;T;A	18;16;14	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3332	22.6	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1050	1052	ATA	23;23;24	A;T;A	14;14;15	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3332	22.6	1	SNP	p	S91F	0	.	.	271	273	TCC	573	575	TCC	40;40;40	T;C;C	26;26;26	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3332	22.6	1	SNP	p	D95N	0	.	.	283	285	GAC	585	587	GAC	40;41;41	G;A;C	27;27;28	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	390	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3332	22.6	1	SNP	p	D95G	0	.	.	283	285	GAC	585	587	GAC	40;41;41	G;A;C	27;27;28	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	531	118	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1334	18.4	0	.	p	.	0	P191fs	FSHIFT	571	571	C	929	929	C	25	C	15	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	531	118	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1334	18.4	1	SNP	p	G45D	0	.	.	133	135	GGC	490	492	GGC	30;32;32	G;G;C	22;22;20	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	94	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	960	17.6	0	.	n	.	0	.206T	INS	206	206	T	535	535	T	37	T	25	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1372	1374	GCC	13;13;11	G;C;C	9;9;8	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1414	1416	GCA	11;13;13	G;C;A	7;9;8	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	1	SNP	p	D86N	0	.	.	256	258	GAC	367	369	GAC	28;28;28	G;A;C	16;17;16	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	1	SNP	p	S87W	0	.	.	259	261	AGT	370	372	AGT	28;28;29	A;G;T	14;16;18	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	1	SNP	p	S87I	0	.	.	259	261	AGT	370	372	AGT	28;28;29	A;G;T	14;16;18	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	1	SNP	p	S87R	0	.	.	259	261	AGT	370	372	AGT	28;28;29	A;G;T	14;16;18	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	338	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2709	23.0	1	SNP	p	S88P	0	.	.	262	264	TCC	373	375	TCC	29;29;29	T;C;C	17;17;17	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	294	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2705	22.1	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1585	1587	GGT	16;16;16	G;G;T	11;11;10	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1099	1101	GCA	52;53;53	G;C;A	35;32;36	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1102	1104	ATC	53;53;53	A,T;T;C	36,1;36;35	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1114	1116	GTG	51;52;52	G;T;G	34;33;34	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1114	1116	GTG	51;52;52	G;T;G	34;33;34	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1618	1620	ACC	24;24;24	A;C;C	16;17;17	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1672	1674	GCG	21;21;21	G;C;G	16;14;14	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1672	1674	GCG	21;21;21	G;C;G	16;14;14	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1795	1797	GGT	32;32;30	G;G;T	21;21;19	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1804	1806	GGC	27;27;27	G;G;C	16;16;16	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	422	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2079	38.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1822	1824	CCG	25;25;25	C;C;G	14;14;16	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	728	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3024	43.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1624	1626	CTG	24;25;25	C;T;G	12;12;13	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	212	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1577	25.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	265	267	GGC	29;29;29	G;G;C	21;21;21	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	212	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1577	25.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	447	447	C	16	C,G	10,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	T18M	NONSYN	52	54	ACG	240	242	ATG	26;26;27	A;T;G	18;16;19	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	I45V	NONSYN	133	135	ATT	321	323	GTT	35;35;34	G;T;T	23;22;24	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	N121S	NONSYN	361	363	AAC	549	551	AGC	20;20;20	A;G;C	16;14;16	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	552	554	AAA	20;20;20	A;A;A	16;16;16	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	579	581	TAT	22;22;22	T;A;T	16;17;16	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	N134K	NONSYN	400	402	AAT	588	590	AAG	22;22;22	A;A;G	17;17;17	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	V135F	NONSYN	403	405	GTG	591	593	TTT	21;21;21	T;T;T	15;16;15	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	606	608	AAA	18;18;18	A;A;A	14;14;14	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	Q143E	NONSYN	427	429	CAA	615	617	GAA	18;18;18	G;A;A	14;14;13	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	639	641	GCA	21;22;20	G;C;A	15;16;15	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	K207_M208insK	INS	619	619	A	807	807	A	26	A	15	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	A212S	NONSYN	634	636	GCA	825	827	TCA	37;38;42	T;C;A	23;22;25	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	228	porB1b	1038	1038	96.37	porB1b.l15.c4.ctg.1	1551	27.4	0	.	p	.	0	Y251fs	FSHIFT	751	751	T	942	942	T	46	T	30	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1176	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4881	47.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2003	2005	CAT	52;52;52	C;A;T	33;33;33	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	128	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1180	22.0	1	SNP	p	V57M	1	.	.	169	171	ATG	577	579	ATG	42;42;42	A;T;G	29;29;29	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
